Holen Sie sich die Stockscreener-App
3.91
1.94%
0.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$3.87
Offen:
$3.84
24-Stunden-Volumen:
2.62M
Relative Volume:
1.01
Marktkapitalisierung:
$530.44M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.3841
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
-45.13%
1M Leistung:
-27.35%
6M Leistung:
-45.28%
1J Leistung:
-45.21%
1-Tages-Spanne:
$3.77
$4.02
1-Wochen-Bereich:
$2.90
$7.73
52-Wochen-Spanne:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.91 | 530.44M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.19 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
526.49 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.93 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
562.46 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.60 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune Announces Multiple Presentations at Upcoming American - GuruFocus
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - The Manila Times
Breakthrough GLP-1/Glucagon Drug Pemvidutide Reveals Multiple Cardiometabolic Benefits in New Clinical Data - Stock Titan
Kalkine : Altimmune’s Role in NASDAQ Composite Amid Biotech Sector Momentum - Kalkine Media
Altimmune, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
Two Sigma Advisers LP Sells 22,700 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Nuveen Asset Management LLC Has $1.56 Million Stock Position in Altimmune, Inc. (NASDAQ:ALT) - Defense World
BNP Paribas Financial Markets Sells 33,984 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Stifel analysts reaffirm Altimmune stock rating with $18 price target By Investing.com - Investing.com South Africa
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
Stifel analysts reaffirm Altimmune stock rating with $18 price target - Investing.com India
Altimmune, Inc. (NASDAQ:ALT) Shares Bought by ProShare Advisors LLC - Defense World
Altimmune, Inc. (NASDAQ:ALT) Stock Holdings Increased by Millennium Management LLC - Defense World
Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire
Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. (NASDAQ:ALT) Shares Bought by Deutsche Bank AG - Defense World
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com India
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook - Investing.com
FY2029 EPS Estimate for Altimmune Decreased by Analyst - Defense World
Wall Street Zen Upgrades Altimmune (NASDAQ:ALT) to “Hold” - Defense World
ALT Hosts Virtual Meeting to Discuss Strategic Developments | ALT Stock News - GuruFocus
Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Northern Trust Corp - Defense World
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential - MSN
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? - Benzinga
Altimmune begins phase 2 trial for AUD treatment By Investing.com - Investing.com South Africa
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluati - GuruFocus
Altimmune (ALT) Begins Phase 2 Trial for Pemvidutide in Treating Alcohol Use Disorder | ALT Stock News - GuruFocus
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder - marketscreener.com
Altimmune begins phase 2 trial for AUD treatment - Investing.com
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Breakthrough AUD Drug Enters Phase 2 Trial: New Hope for 28 Million US Patients With Alcohol Use Disorder - Stock Titan
HC Wainwright Has Strong Forecast for Altimmune Q2 Earnings - Defense World
William Blair Estimates Altimmune’s Q2 Earnings (NASDAQ:ALT) - Defense World
Price T Rowe Associates Inc. MD Acquires 4,158 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
B. Riley Issues Positive Estimate for Altimmune Earnings - Defense World
(ALT) Proactive Strategies - news.stocktradersdaily.com
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN
Baird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT) - The AM Reporter
Stifel Financial Corp Sells 4,649 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey
Voya Investment Management LLC Decreases Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN
Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia
Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria
Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences | ALT Stock News - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan
Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
0.27%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):